Labcorp announced on February 23, 2026 that it is expanding its collaboration with PathAI to deploy AISight Dx, an FDA-cleared digital pathology platform, across Labcorp’s national network of anatomic pathology labs and hospital partnerships. The move takes an AI diagnostic tool that has been cleared for years in narrow pilot settings and pushes it into one of the largest clinical laboratory operations in the United States.
What AISight Dx does inside a working lab
AISight Dx is a cloud-based image management system that lets pathologists view, annotate, and manage whole-slide images digitally rather than under a physical microscope, while layering AI-powered image analysis on top to support diagnostic steps. The FDA originally cleared AISight Dx for primary diagnosis in June 2025, and the agency later expanded that clearance to cover additional slide scanners — including Roche’s VENTANA DP 200 and DP 600 — through a Predetermined Change Control Plan, a newer FDA mechanism that lets PathAI add supported hardware and software updates without filing a fresh 510(k) application each time. PathAI says AISight Dx was the first digital pathology image management system to receive that kind of pre-authorized change pathway.
Why Labcorp, and why now
Labcorp’s relationship with PathAI dates back to a strategic investment in 2019 and a 2021 collaboration focused on using AI to support clinical trial pathology work for drug developers. The February 2026 announcement extends that partnership into Labcorp’s core diagnostic business, incorporating digital pathology workflows to support the company’s precision medicine testing alongside routine anatomic pathology cases. For a company that processes millions of pathology specimens annually, moving from glass slides to a digital, AI-assisted workflow is a logistical undertaking on a different scale than a single hospital system adopting the same software — it requires scanner infrastructure, IT integration, and pathologist retraining across dozens of facilities.
The promise: faster, more consistent results
PathAI and Labcorp frame the deployment around three benefits: faster turnaround times, more consistent diagnostic quality across geographically dispersed labs, and better collaboration between pathologists who can now review the same digital case remotely rather than shipping physical slides between locations. Digital pathology advocates have long argued that glass slides create bottlenecks — a rare or complex case might need a subspecialist’s second opinion, but shipping a physical slide across the country can add days to a diagnosis, whereas a digital image can be shared instantly.
The skeptical view from inside pathology
Not every pathologist is enthusiastic about large-scale digital conversion. Some in the field have raised concerns that digitizing at national scale, driven by a lab-services company’s operational goals, risks prioritizing throughput and cost savings over the individualized attention some complex cases require. There are also unresolved questions about liability and workflow when an AI system assists in a primary diagnosis at the volume Labcorp handles: regulatory clearance establishes that a tool is safe and effective for its intended use, but it does not eliminate the pathologist’s ultimate responsibility for sign-off, and some professional groups have pushed for clearer guidelines on how much weight an AI-generated flag should carry in a signed report.
Part of a broader digital pathology land grab
Labcorp’s expansion lands amid a wave of pathology AI announcements in 2026, including Leica Biosystems’ clearance of quality-control software and Artera’s clearance of a breast cancer risk-stratification tool. Quest Diagnostics, Labcorp’s chief rival in the commercial lab industry, has pursued its own digital pathology partnerships, meaning the two largest U.S. lab companies are now effectively racing to convert their anatomic pathology operations to AI-assisted digital workflows before the other locks in a supplier relationship and scale advantage.
What to watch next
The real test of Labcorp’s rollout will be turnaround-time and error-rate data gathered after AISight Dx is running at meaningful volume across its labs, rather than in a pilot. Investors and hospital partners will also be watching whether Labcorp’s scale becomes a selling point PathAI can use to win additional national lab and health system customers, and whether the Predetermined Change Control Plan framework that let PathAI add scanners without new FDA filings becomes a template other digital pathology vendors push regulators to adopt. Pathologists inside Labcorp’s network will also be watched closely for how quickly they adapt to reading primarily digital cases, a workflow change that touches nearly every pathologist in the company regardless of subspecialty.
